Status:

COMPLETED

Low-dose Versus Standard Dose Alteplase in Acute Ischemic Stroke , 4 Monthes Prospective Study

Lead Sponsor:

Department of Medical Services Ministry of Public Health of Thailand

Collaborating Sponsors:

Lumpang Hospital

Conditions:

Acute Stroke

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

Cohort A Randomized Control trial of Ateplase 0.6, 0.75 and 0.9 mg/kg in 78 patients Cohort B single arm 0.9 mg/kg Ateplase in 330 patients Combined Cohort A and B evaluate different of death, intra-c...

Detailed Description

We conducted the prospective study to compare the low-dose and standard-dose rtPa and identify the important factors predicted stroke outcomes in acute stroke patient received intravenous rtPa. In Coh...

Eligibility Criteria

Inclusion

  • Diagnosis of Acute ischemic stroke
  • Age 18 to 80 years
  • Onset of stroke symptoms with in 4.5 hours before initiation of study-drug administration
  • Stroke symptoms present for at least 30 minutes with no significant improvement before treatment

Exclusion

  • patients with Intracranial hemorrhage
  • the symptoms of Time onset was unknown
  • Symptoms rapidly improving or only minor before start of infusion
  • Seizure at the onset of stroke
  • Stroke or serious head trauma within the previous 3 months
  • Administration of heparin within the 48 hours preceding the onset of stroke, with an activate
  • partial-thromboplastin time at presentation exceeding the upper limit of the normal range
  • Platelet count of less than 100,000 per cubic millimeter
  • Systole pressure greater than 185 mm Hg or diastole pressure greater than 110 mm Hg, or aggressive treatment intravenous medication) necessary to reduce blood pressure to these limits
  • Blood glucose less than 50 mg per deciliter or greater than 400 mg per deciliter
  • Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal
  • Oral anticoagulant treatment
  • Major surgery or severe trauma within the previous 3 months
  • Other major disorders associated with an increased risk of bleeding

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 14 2019

Estimated Enrollment :

408 Patients enrolled

Trial Details

Trial ID

NCT03847883

Start Date

January 1 2011

End Date

February 14 2019

Last Update

February 20 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assistant Professor Subsai Kongsaengdao

Bangkok, Thailand, 10400

Low-dose Versus Standard Dose Alteplase in Acute Ischemic Stroke , 4 Monthes Prospective Study | DecenTrialz